Eligible studies included those that: (1) assessed the relationship between α-Klotho levels and CSA-AKI, (2) used validated assays for α-Klotho in blood, urine, or tissue, and (3) reported CSA-AKI incidence as a primary outcome. The gene discussed is KL; the disease is acute kidney injury.